Rituximab: new indication. Lymphoma maintenance therapy: inadequate follow-up.
Favourable short-term results need longer-term confirmation in terms of effects on survival; they also need to be weighed against the risk of serious adverse effects (infections, cardiac and gastrointestinal disorders).
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D005602:France; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013534:Survival
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents